Cure8 research brief
IL-22 links microbial metabolites to epithelial repair and inflammation; clarifying these pathways could inform future therapies or dietary/microbiome approaches to promote mucosal healing without worsening inflammation.
Clinicians and researchers studying IBD mechanisms or novel therapies; adult patients interested in microbiome–metabolite influences on disease and mucosal healing.
This article summarizes mechanistic and associative evidence connecting specific microbial metabolites to IL-22 production, bioavailability, and signaling.
The strongest mechanistic support is described for short-chain fatty acids and tryptophan–AhR pathways regulating IL-22; bile acid effects are reported as metabolite- and receptor-dependent; the TMA/TMAO link is presented as a hypothesis with mainly indirect evidence.
The review emphasizes that whether IL-22 is beneficial or harmful depends on multiple context factors: duration and magnitude of exposure, cellular sources, the balance with IL-22 binding protein (IL-22BP), epithelial cell state, concurrent inflammatory signals, and overall disease context.
For patients this means research is still clarifying when manipulating microbiota or metabolites might help. The review separates well-supported mechanisms from associative or hypothesis-generating ideas to guide future studies.
This item is a journal review (abstract-level content provided). It synthesizes existing mechanistic and associative studies rather than reporting new clinical trial results; some proposed links (notably TMA/TMAO to IL-22) remain hypothesis-generating and need experimental validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests that polyphenols can change gut bacteria and metabolite production differently in people with IBD versus healthy controls, which could matter for designing personalized dietary interventions.
The study suggests that in some people with IBD who have Candida overgrowth, systemic antifungal therapy (fluconazole) can change gut microbes and metabolites in ways linked to better disease activity over 8 weeks. That...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
